Syensqo (SYENS)
Euronext Brussels · Belgium · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 77.15 |
|---|---|
| 52-week range | 41.76 – 83.40 |
| Return, 1 month / 3 months | −2.4% / +10.7% |
| Return, 1 year / 3 years | +14.1% / – |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 41 |
| Volatility (1 year) | 50.6% |
| Worst drawdown (1 year) | -47.1% |
| Average daily value traded | 11.03M EUR |
| Dividend yield | 2.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Syensqo is a specialty chemicals and materials company based in Brussels, Belgium. It develops and supplies advanced materials, specialty polymers, composites and chemical solutions for customers in industries such as aerospace, automotive, electronics, healthcare and consumer goods. Its products are used in lightweight parts, coatings, batteries and medical applications, and the company serves manufacturers and industrial clients around the world through its materials and chemistry businesses.
The shares are listed on the Euronext Brussels in Belgium under the code SYENS, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Syensqo (SYENS) trades on the Euronext Brussels in Belgium. It last closed at EUR 77.15 on 22 October 2026.
Its price-based Market X-Ray is 65 out of 100 (a fair price profile), ranking 34 of 111 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 14.1% and over the last three months it rose 10.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Brussels
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 90 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 14.4% | ||
| From 52-week high | -7.0% | ||
| Momentum | 86 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 10.7% | ||
| 6-month return | 43.3% | ||
| 12-month return, skipping the last month | 16.9% | ||
| Stability (higher is calmer) | 20 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 50.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -47.1% | ||
| Liquidity | 95 · Strong | Trades actively. | |
| Average daily value traded | 11.03M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 20 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.1% | ||
| Years with dividends | 3 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −7.0% |
|---|---|
| 1 month | −2.4% |
| 3 months | +10.7% |
| 6 months | +43.3% |
| 1 year | +14.1% |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 79.74 / 67.45 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.66 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 May 2026 | EUR 1.6200 |
| 15 May 2025 | EUR 1.6200 |
| 29 May 2024 | EUR 1.6200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Brussels; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.